Literature DB >> 30464685

Access to care and outcomes for neuroendocrine tumours: does socioeconomic status matter?

J Hallet1,2,3,4, N G Coburn2,3,4, S Singh1,3,4,5, K Beyfuss4, S Koujanian4, N Liu3, C H L Law1,2,4.   

Abstract

Introduction: Neuroendocrine tumours (nets) are a poorly understood malignancy lacking standardized care. Differences in socioeconomic status (ses) might worsen the effect of non-standardized care. We examined the effect of ses on net peri-diagnostic care patterns and outcomes.
Methods: In this population-based cohort study, net cases identified from a provincial cancer registry (1994-2009) were divided into low (1st and 2nd income quintiles) and high (3rd, 4th, and 5th quintiles) ses groups. We compared peri-diagnostic health care utilization (-2 years to +6 months), metastatic recurrence, and overall survival (os) between the groups.
Results: Of 4966 net patients, 38.3% had a low ses. Neither the primary net sites (p = 0.15), nor the metastatic presentation (p = 0.31) differed. Patients with low ses had a higher mean number of physician visits (20.1 ± 19.9 vs. 18.1 ± 16.5, p = 0.001) and imaging studies (56 ± 50 vs. 52 ± 44, p = 0.009) leading to the net diagnosis. Rates of primary tumour resection (p = 0.14), hepatectomy (p = 0.45), systemic therapy (p = 0.38), and liver embolization (p = 0.13) did not differ with ses. In the low-ses group, metastatic recurrence was more likely (41.1% vs. 37.6%, p = 0.01) during a median follow-up of 61.7 months, and the 10-year os was inferior (47.1% vs. 52.2%, p < 0.01). Low ses was associated with worse os (hazard ratio: 1.16; 95% confidence interval: 1.06 to 1.26) after adjustment for age, sex, comorbidity burden, primary net site, and rural living. Conclusions: Low ses was associated with more physician visits and imaging before a net diagnosis, but not with more advanced stage at presentation nor with an effect on the pattern of therapy. Long-term outcomes were inferior in the low-ses group. These data can help to inform the design of health care delivery for nets.

Entities:  

Keywords:  Neuroendocrine tumours; carcinoids; income; outcomes; socioeconomics

Mesh:

Year:  2018        PMID: 30464685      PMCID: PMC6209547          DOI: 10.3747/co.35.3930

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  46 in total

1.  Associations between community income and cancer survival in Ontario, Canada, and the United States.

Authors:  C Boyd; J Y Zhang-Salomons; P A Groome; W J Mackillop
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

2.  Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies.

Authors:  D H Brewster; C S Thomson; D J Hole; R J Black; P L Stroner; C R Gillis
Journal:  BMJ       Date:  2001-04-07

3.  Social class, health and aging: socioeconomic determinants of self-reported morbidity among the noninstitutionalized elderly in Canada.

Authors:  J Cairney; R Arnold
Journal:  Can J Public Health       Date:  1996 May-Jun

4.  Variation in health and health care use by socioeconomic status in Winnipeg, Canada: does the system work well? Yes and no.

Authors:  N P Roos; C A Mustard
Journal:  Milbank Q       Date:  1997       Impact factor: 4.911

5.  Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.

Authors:  Julie Hallet; Calvin How Lim Law; Moises Cukier; Refik Saskin; Ning Liu; Simron Singh
Journal:  Cancer       Date:  2014-10-13       Impact factor: 6.860

6.  Socio-economic status and visits to physicians by adults in Ontario, Canada.

Authors:  W McIsaac; V Goel; D Naylor
Journal:  J Health Serv Res Policy       Date:  1997-04

7.  Cancer risk and social inequalities in Italy.

Authors:  F Faggiano; R Zanetti; G Costa
Journal:  J Epidemiol Community Health       Date:  1994-10       Impact factor: 3.710

Review 8.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

9.  Socioeconomic status and cancer mortality and incidence in Melbourne.

Authors:  J Williams; C Clifford; J Hopper; G Giles
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

10.  An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer.

Authors:  L M Forrest; D C McMillan; C S McArdle; D J Dunlop
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

View more
  1 in total

1.  Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care.

Authors:  Braden Woodhouse; Sharon Pattison; Eva Segelov; Simron Singh; Kate Parker; Grace Kong; William Macdonald; David Wyld; Goswin Meyer-Rochow; Nick Pavlakis; Siobhan Conroy; Vallerie Gordon; Jonathan Koea; Nicole Kramer; Michael Michael; Kate Wakelin; Tehmina Asif; Dorothy Lo; Timothy Price; Ben Lawrence
Journal:  J Clin Med       Date:  2019-09-12       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.